Licoagrochacone A

Licoagrochacone A

SCHEMBL30383634

C=CC(C)(C)c1cc(/C=C/C(=O)c2ccc(O)cc2)c(OC)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 13/20 1.00
DPP4 P27487 4/20 1.00
ABCG2 Q9UNQ0 2/20 1.00
IDH1 O75874 1/20 1.00
ABCB1 P08183 1/20 1.00
UGT1A1 P22309 1/20 1.00
ABCC1 P33527 1/20 1.00
PRMT6 Q96LA8 1/20 1.00
CAPN1 P07384 1/20 0.60
CTSL P07711 1/20 0.60
CTSB P07858 1/20 0.60
TDP1 Q9NUW8 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Licoagrochacone A SCHEMBL29929441 1.00 PTPN1 (1.00) PTPN1DPP4ABCG2IDH1ABCB1
Licoagrochacone A SCHEMBL4906294 1.00 PTPN1 (1.00) PTPN1DPP4ABCG2IDH1ABCB1
Licoagrochacone A SCHEMBL114042 1.00 PTPN1 (1.00) PTPN1DPP4ABCG2IDH1ABCB1
SCHEMBL24026322 0.92 PTPN1 (0.85) PTPN1DPP4ABCG2IDH1ABCB1
SCHEMBL7191524 0.92 PTPN1 (1.00) PTPN1DPP4ABCG2IDH1ABCB1
SCHEMBL7191527 0.92 PTPN1 (1.00) PTPN1DPP4ABCG2IDH1ABCB1
Licoagrochacone A SCHEMBL25196053 0.89 PTPN1 (0.80) PTPN1DPP4ABCG2IDH1ABCB1
SCHEMBL7187524 0.88 PTPN1 (0.79) PTPN1DPP4ABCG2IDH1ABCB1
SCHEMBL7187519 0.88 PTPN1 (0.79) PTPN1DPP4ABCG2IDH1ABCB1
SCHEMBL7178841 0.88 PTPN1 (0.78) PTPN1DPP4ABCG2IDH1ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B PTPN1 1308/4885DPP4 4226/4885ABCG2 1606/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 PTPN1 1520/4885DPP4 3670/4885ABCG2 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.